OTTAWA, May 20 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) Collagenna Skin Care Products has entered into a distribution agreement with the Texas Beauty Institute of the Dallas/Fort Worth Area
www.texasbeautyinstitute.com
The Texas Beauty Institute (TBI) is a leader in the field of non-invasive cosmetic recovery solutions and is constantly doing research to develop natural anti-aging techniques. TBI has researched and developed protocols for advanced micro current therapies which maximize the penetration of elastin and collagen into the skin.
Collagenna Skin Care Products CEO Michael Arnkvarn states, "When we first started talking with TBI's CEO, Mr Nelson Thibodeaux, it became very apparent that our companies were a good fit. Our collagen and peptide technologies used in combination with TBI's infusion therapies will give maximum results. As well TBI works with Chiropractors all over the USA and this will offer a tremendous opportunity to market our Melem Secret line of supplements as part of their message of natural health. We have started putting in place a marketing program in the Dallas/Fort Worth area to help TBI introduce the Collagenna product line."
The Texas Beauty Institute will distribute the Collagenna product line to other clinics as well as sell the product to their retail customers. They have recently updated their website and the Collagenna Product line can be purchased by retail customers on their ecommerce site as well as by their wholesale clients in the site's backroom.
Collagenna Skin care Products/Melem Secret is continuing its global expansion in order to meet its financial targets for 2010. TBI is another important partner in this equation
The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
Advertisement
The Texas Beauty Institute (TBI) is a leader in the field of non-invasive cosmetic recovery solutions and is constantly doing research to develop natural anti-aging techniques. TBI has researched and developed protocols for advanced micro current therapies which maximize the penetration of elastin and collagen into the skin.
Advertisement
Collagenna Skin Care Products CEO Michael Arnkvarn states, "When we first started talking with TBI's CEO, Mr Nelson Thibodeaux, it became very apparent that our companies were a good fit. Our collagen and peptide technologies used in combination with TBI's infusion therapies will give maximum results. As well TBI works with Chiropractors all over the USA and this will offer a tremendous opportunity to market our Melem Secret line of supplements as part of their message of natural health. We have started putting in place a marketing program in the Dallas/Fort Worth area to help TBI introduce the Collagenna product line."
The Texas Beauty Institute will distribute the Collagenna product line to other clinics as well as sell the product to their retail customers. They have recently updated their website and the Collagenna Product line can be purchased by retail customers on their ecommerce site as well as by their wholesale clients in the site's backroom.
Collagenna Skin care Products/Melem Secret is continuing its global expansion in order to meet its financial targets for 2010. TBI is another important partner in this equation
The company reminds our shareholders and followers that the company does not subscribe to the PinkSheets.Com Filing Service. Its IR company web site section "CLIENT SUPPORT" TAB www.minamargroup.net or this direct link http://minamarmarketinggroup.helpserve.com/ should be reviewed by its followers for further updates on this and other business matters. Non-newsworthy events are not press released however posted on this separate support sites to keep our followers advised of day-to-day events, and the company corporate web site. For any matters relating to retail investor queries or to send us the company directly a message please click on the "INVESTOR SUPPORT" TAB or this direct link www.minamargroup.net/helpdesk.
To be included in company's email database for press releases, industry updates, and non-weekly activity at the company that may or may not be news released, please subscribe or opt in mailer at www.minamargroup.com/updates.
Safe Harbor Statement
Information in this filing may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases, Inc. that constitute forward-looking statements for purposes of the safe harbor Provision's under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project," and similar words and phrases are intended to identify such forward-looking statements. HTDS Corporation cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases, Inc. is not a guarantee of future performance. None of the information in this filing constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases, Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases, Inc.'s control. In addition to those discussed in Hard to Treat Diseases, Inc.'s press releases, public filings, and statements by Hard to Treat Diseases, Inc.'s management, including, but not limited to, Hard to Treat Diseases, Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases, Inc.'s ability to raise additional capital to fund future operations, HTDS Corporation's ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities and, in identifying contracts which match Hard to Treat Diseases, Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases, Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For medical and scientific dialogue inquiry only, please contact [email protected]; For any corporate matters, please contact www.minamargroup.com/helpdesk
SOURCE Hard to Treat Diseases
